Medizinische Universität Innsbruck
Medizinische Universität Innsbruck
Innsbruck, Austria8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05444257 | |
| HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Polyuria, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 3 | 2026-08-25 | NCT05373264 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Recruiting | Phase 2 / Phase 3 | 2026-05-26 | NCT05416307 | |
| Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-04-13 | NCT06419946 | |
| Safe and Timely Antithrombotic Removal (STAR) Registry | Blood Loss, Surgical, Hemorrhage, Intraoperative Complications, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Hemorrhage | Recruiting | Not stated | 2025-07-16 | NCT05077124 | |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | Active, not recruiting | Phase 3 | 2024-10-17 | NCT04769895 |